文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌保留尿道立体定向体部放疗:使用或不使用直肠内球囊时直肠壁剂量可降低多少?

Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
PubMed 文献 · Radiat Oncol · 2018-06-19

本剂量学比较研究基于一项保留尿道前列腺癌立体定向体部放疗(SBRT)随机II期试验,对10例前列腺癌患者分别在有和无直肠内球囊(ERB)条件下模拟并制定计划,采用标准化四步序贯优化方法压低直肠壁(Rwall)低至中等剂量约束,结果显示无论是否使用ERB,Rwall低至中等剂量均可显著降低,且靶区剂量均匀性保持稳定。

要点

  • 四步序贯优化(Vm4)使Rwall的D30%、D40%、D50%和Dmed降低一半,D60%降低三分之一,靶区均匀性稳定。
  • Vm5时PTV均匀性指数(HIPTV)无论是否使用ERB均变差,提示优化不宜超过四步。
  • 除股骨头D2%在有无ERB时存在差异外,配对计划间Rwall和膀胱壁剂量学参数无统计学差异。

核心结论

  • 在保留尿道的前列腺癌SBRT中,进一步优化Rwall是可行的,且不损害靶区剂量均匀性。
  • 无论是否使用ERB,采用四步序贯优化方法均可显著降低Rwall的低至中等剂量。

研究设计与样本

  • 剂量学比较研究,纳入10例前列腺癌患者,分别在有和无ERB条件下进行模拟和计划设计。
  • 处方剂量为PTV 36.25Gy(7.25Gy×5次),尿道计划风险体积(uPRV)32.5Gy。
  • 参考计划(Vmref)满足PTV和uPRV覆盖目标及危及器官剂量约束,再经标准化五步序贯优化(Vm1至Vm5)逐步压低Rwall低至中等剂量约束,获得有无ERB的配对计划。

主要发现

  • 与Vmref相比,Vm4使Rwall的D30%、D40%、D50%和Dmed降低一半,D60%降低三分之一,而HIPTV、HIuPRV和DSC在有无ERB时均保持稳定。
  • Vm5时HIPTV在有无ERB时均变差。
  • 配对计划间Rwall和膀胱壁(Bwall)剂量学参数无统计学差异,仅股骨头(FHeads)D2%在有无ERB时存在差异。

关键数值与推荐

  • PTV处方剂量36.25Gy(7.25Gy×5次),uPRV处方剂量32.5Gy。
  • Vm4使Rwall的D30%、D40%、D50%和Dmed降低一半,D60%降低三分之一。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This is a dosimetric comparative study intended to establish appropriate low-to-intermediate dose-constraints for the rectal wall (Rwall) in the context of a randomized phase-II trial on urethra-sparing stereotactic body radiotherapy (SBRT) for prostate cancer. The effect of plan optimization on low-to-intermediate Rwall dose and the potential benefit of an endorectal balloon (ERB) are investigated. METHODS: Ten prostate cancer patients, simulated with and without an ERB, were planned to receive 36.25Gy (7.25Gyx5) to the planning treatment volume (PTV) and 32.5Gy to the urethral planning risk volume (uPRV). Reference plans with and without the ERB, optimized with respect to PTV and uPRV coverage objectives and the organs at risk dose constraints, were further optimized using a standardized stepwise approach to push down dose constraints to the Rwall in the low to intermediate range in five sequential steps to obtain paired plans with and without ERB (Vm1 to Vm5). Homogeneity index for the PTV and the uPRV, and the Dice similarity coefficient (DSC) for the PTV were analyzed. Dosimetric parameters for Rwall including the median dose and the dose received by 10 to 60% of the Rwall, bladder wall (Bwall) and femoral heads (FHeads) were compared. The monitor units (MU) per plan were recorded. RESULTS: Vm4 reduced by half D30%, D40%, D50%, and Dmed for Rwall and decreased by a third D60% while HIPTV, HIuPRV and DSC remained stable with and without ERB compared to Vmref. HIPTV worsened at Vm5 both with and without ERB. No statistical differences were observed between paired plans on Rwall, Bwall except a higher D2% for Fheads with and without an ERB. CONCLUSIONS: Further optimization to the Rwall in the context of urethra sparing prostate SBRT is feasible without compromising the dose homogeneity to the target. Independent of the use or not of an ERB, low-to-intermediate doses to the Rwall can be significantly reduced using a four-step sequential optimization approach.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dubouloz A, Rouzaud M, Tsvang L, et al. Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon? Radiat Oncol. 2018. PMID: 29921291. doi:10.1186/s13014-018-1059-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。